Abstract:Hypertension is a major risk factor for cardiovascular diseases such as stroke and heart failure. Recent studies have shown that changes in the composition and function of the gut microbiota are closely related to the onset and development of hypertension. However, the individual differences in gut microbiota species make it difficult for traditional analysis methods to effectively reveal the pathogenic mechanisms of hypertension. In contrast, the inter-individual variability in gut microbial metabolites is much smaller, allowing for better cross-individual comparisons and reducing confounding factors in analysis. The interactions between gut microbiota and metabolites are highly complex, and network analysis can systematically capture this complexity. In this study Flux Balance Analysis (FBA) was utilized to predict the metabolic flux of gut microbiota and constructed cross-feeding networks. Random Forest and XGBoost models were employed to identify metabolites associated with hypertension. A differential microbial correlation network was used to analyze important metabolically related microbial sub-networks, and ultimately, the metabolic abnormalities and metabolite-related pathways were analyzed at the network level using the metabolite correlation network and cross-feeding networks. It was observed that the interaction patterns among 25 species--collectively referred to as the KEPR guild, with the most abundant genera being Eubacterium, Ruminococcus, Klebsiella, and Parabacteroides--changed, leading to alterations in 12 metabolites, such as choline (chol), 1-butanol (btoh), trimethylamine (tma), cytidine (cytd), and betaine (glyb) etc. Choline can be oxidized to form betaine, thereby affecting host blood pressure. Abnormalities in siroheme and methanethiol may result in reduced secretion of hydrogen sulfide by microbes, which in turn impacts blood pressure regulation mechanisms. The changes in these 12 metabolites may also enhance the degradation of mucin-type O-glycans and reduce butyrate metabolic activity, weakening the protective ability of intestinal epithelial cells. This may lead to inflammation and oxidative stress, exacerbating endothelial cell damage and consequently resulting in endothelial dysfunction and increased blood pressure. The findings of this study provide new insights into the pathogenic mechanisms of hypertension and offer potential targets for clinical intervention.

Metabolomic Characterization of Hypertension and Dyslipidemia.

Identification of Potential Metabolic Markers of Hypertension in Chinese Children.

Identification of biomarkers for essential hypertension based on metabolomics

Identification of Serum Biomarkers of Ischemic Stroke in a Hypertensive Population Based on Metabolomics and Lipidomics

Cross-Sectional Blood Metabolite Markers of Hypertension: A Multicohort Analysis of 44,306 Individuals from the COnsortium of METabolomics Studies

Integrated Omic Analysis of Human Plasma Metabolites and Microbiota in a Hypertension Cohort

Unique intestinal microflora and metabolic profile in different stages of hypertension reveal potential biomarkers for early diagnosis and prognosis

Comprehensive Metabolomics and Machine Learning Identify Profound Oxidative Stress and Inflammation Signatures in Hypertensive Patients with Obstructive Sleep Apnea

Metabonomics Study of Essential Hypertension and Its Chinese Medicine Subtypes by Using Gas Chromatography-Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy

Abstract P311: Metabolomic Associations With Blood Pressure and Hypertension in Multi-Ethnic Populations

The interactions and biological pathways among metabolomics products of patients with coronary heart disease

Altered adolescents obesity metabolism is associated with hypertension: a UPLC-MS-based untargeted metabolomics study

Gut microbial metabolic flux disorder in hypertension

Characterization of metabolic responses to healthy diets and association with blood pressure: application to the Optimal Macronutrient Intake Trial for Heart Health (OmniHeart), a randomized controlled study

Lipidomic Profiling Identifies Signatures of Metabolic Risk.

Development and Validation of a Sensitive and Reliable Targeted Metabolomics Method for the Quantification of Cardiovascular Disease-Related Biomarkers in Plasma Using Ultrahigh-Performance Liquid Chromatography-Tandem Mass Spectrometry

Discovery of Metabolite Profiles of Metabolic Syndrome Using Untargeted and Targeted LC–MS Based Lipidomics Approach

Study on Urine Metabolic Profiling and Pathogenesis of Hyperlipidemia.

Discovery and Comparison of Serum Biomarkers for Diabetes Mellitus and Metabolic Syndrome Based on UPLC-Q-TOF/MS

Biomarker identification and risk assessment of cardiovascular disease based on untargeted metabolomics and machine learning

Metabolomic differences and interactions between coronary heart disease and diabetes mellitus: Pathogenesis understanding and auxiliary diagnosis